Atrial fibrillation (AF) is a chronic heart rhythm disorder, characterized by exacerbations interspersed with clinical remissions. Antiarrhythmic drugs (AADs) are traditionally considered to be the preferred initial therapy for the maintenance of sinus rhythm however, these medications have modest efficacy and significant adverse effects. Recent clinical trials have evaluated the role of catheter ablation as the initial therapeutic intervention, demonstrating that cryoballoon ablation significantly reduces atrial tachyarrhythmia recurrence and arrhythmia burden, produces clinically meaningful improvements in symptoms and quality of life, and significantly decreases healthcare resource utilization. In contrast to AADs, catheter ablation appears to be a disease modifying therapy, significantly reducing the progression to more advanced forms of AF. These findings are relevant to patients, providers, and healthcare systems, helping inform the decision regarding the initial choice of rhythm-control therapy in patients with treatment-naïve AF.